Uncommon and Rare Human Papillomavirus Genotypes Relating to Cervical Carcinomas
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Human papillomavirus (HPV) is an oncogenic virus in cervical cancer and most invasive carcinomas (ICs) are caused by HPV16 and 18. However, the roles and contributions of other uncommon and rare genotypes remain uncertain. Methods: HPV genotypes were retrospectively assessed using an HPV DNA chip that can specify up to 32 HPV genotypes. We arbitrarily regarded genotypes accounting for less than 6% of the total as uncommon and rare genotypes. Results: A total of 3,164 HPV-positive cases were enrolled. In groups 2A, 2B, 3, and unclassified HPV genotypes, 2.4% of cases with uncommon HPV genotypes (68, 26, 34, 53, 66, 69, 70, 73, 40, 42, 43, 44, 54, 55, 61, 62, 6, and 11) showed high grade squamous intraepithelial lesions and ICs. There were no HPV32- and 57-infected cases. Conclusions: We found that the uncommon and rare HPV genotypes may provide incremental etiologic contributions in cervical carcinogenesis, especially HPV68, 70, and 53. Further studies on these uncommon and rare HPV genotypes will be of importance in establishing the significance of genotypes in different regions, especially in planning a strategy for further vaccine development as well as follow-up on the effectiveness of the currently used vaccines.
Abstract
Background: Human papillomavirus (HPV) is an oncogenic virus in cervical cancer and most invasive carcinomas (ICs) are caused by HPV16 and 18. However, the roles and contributions of other uncommon and rare genotypes remain uncertain. Methods: HPV genotypes were retrospectively assessed using an HPV DNA chip that can specify up to 32 HPV genotypes. We arbitrarily regarded genotypes accounting for less than 6% of the total as uncommon and rare genotypes. Results: A total of 3,164 HPV-positive cases were enrolled. In groups 2A, 2B, 3, and unclassified HPV genotypes, 2.4% of cases with uncommon HPV genotypes (68, 26, 34, 53, 66, 69, 70, 73, 40, 42, 43, 44, 54, 55, 61, 62, 6, and 11) showed high grade squamous intraepithelial lesions and ICs. There were no HPV32- and 57-infected cases. Conclusions: We found that the uncommon and rare HPV genotypes may provide incremental etiologic contributions in cervical carcinogenesis, especially HPV68, 70, and 53. Further studies on these uncommon and rare HPV genotypes will be of importance in establishing the significance of genotypes in different regions, especially in planning a strategy for further vaccine development as well as follow-up on the effectiveness of the currently used vaccines.
참고문헌 (21)
- Soerjomataram I, "Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions", Lancet, 380, pp.1840~1850 (2012)
- Oh JK, "Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey", Vaccine, 28, pp.1854~1860 (2010)
- Jovanović AM, "Correlation of human papilloma virus infection with cytology, colposcopy and histopathological examination of the bioptic tissue in low- and high-grade intraepithelial lesions", Eur J Gynaecol Oncol, 33, pp.512~516 (2012)
- de Villiers EM, "Classification of papillomaviruses", Virology, 324, pp.17~27 (2004)
- 홍성란, "Prevalence and Genotype Distribution of Cervical Human Papillomavirus DNA in Korean Women: A Multicenter Study", Journal of Pathology and Translational Medicine, 43(4), pp.342~350 (2009), 대한병리학회
- Bello BD, "Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions", J Med Virol, 81, pp.703~712 (2009)
- Watari H, "High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer", Pathobiology, 78, pp.220~226 (2011)
- Alemany L, "Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention", Gynecol Oncol, 124, pp.512~517 (2012)
- de Mattos AT, "Diversity and uncommon HPV types in HIV seropositive and seronegative women attending an STI clinic", Braz J Microbiol, 42, pp.786~793 (2011)
- Longuet M, "Two novel genital human papillomavirus (HPV) types, HPV68 and HPV70, related to the potentially oncogenic HPV39", J Clin Microbiol, 34, pp.738~744 (1996)
- Malik ZA, "Predictors of seropositivity to human papillomavirus type 53: one of the most prevalent high risk-related cervical human papillomaviruses", Viral Immunol, 21, pp.371~377 (2008)
- IARC, "Human papillomaviruses", IARC Monogr Eval Carcinog Risks Hum, 100B, pp.1~475 (2011)
- Forman D, "Global burden of human papillomavirus and related diseases", Vaccine, 30(Suppl 5), pp.F12~F23 (2012)
- de Sanjose S, "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study", Lancet Oncol, 11, pp.1048~1056 (2010)
- Li N, "Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication", Int J Cancer, 128, pp.927~935 (2011)
- 최인호, "Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine Cervix", Journal of Pathology and Translational Medicine, 45(6), pp.612~620 (2011), 대한병리학회
- Dunne EF, "Prevalence of HPV infection among females in the United States", JAMA, 297, pp.813~819 (2007)
- Meyer T, "Distribution of HPV 53, HPV 73, and CP8304 in genital epithelial lesions with different grades of dysplasia", Int J Gynecol Cancer, 11, pp.198~204 (2001)
- 이동섭, "Reverse Blot Hybridization Assay를 이용한 강원지역에서의 인유두종바이러스 유전형의 분포도 조사", Journal of Pathology and Translational Medicine, 45(4), pp.348~353 (2011), 대한병리학회
- Lee SA, "Multiple HPV infection in cervical cancer screened by HPVDNAChip", Cancer Lett, 198, pp.187~192 (2003)
- Wheeler CM, "Cross-protective efficacy of HPV-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PA-TRICIA trial, 2012, pp.13, 100~110